Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
← catalyst calendarNCT06952660 · readout in 847 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Genmab.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
100estimated
Sites
129
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-07 | actual | When the study began enrolling |
| Primary completion | 2028-12-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-13 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cervical Cancer
Intervention
- Drug: TIVDAK
Primary outcome
what the primary-completion date above is the date OFType, incidence and severity of ocular adverse events (AEs)
measured 90 days after the last dose of tisotumab vedotin
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed